|Date||Title and Summary||View|
|Jun 21, 2007||
Intra-Cellular Therapies Initiates Phase I Clinical Program for Schizophrenia and Sleep Maintenance Disorders.
|Jun 1, 2005||
Intra-Cellular Therapies, Inc. Receives Exclusive License for Central Nervous System Compounds from Bristol-Myers Squibb Company.
Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.